TFF Pharmaceuticals Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
20 mars 2024 12h00 HE
|
TFF Pharmaceuticals, Inc.
FORT WORTH, March 20, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the “Company” or “TFF Pharmaceuticals”), a clinical-stage biopharmaceutical company focused on developing and...
TFF Pharmaceuticals Announces Update on Clinical Programs
20 mars 2024 09h03 HE
|
TFF Pharmaceuticals, Inc.
Company to Prioritize Clinical Development of Tacrolimus Inhalation Powder (TFF TAC) based on Positive Phase 2 Data, the Potential to Address a Significant Unmet Need in Lung Transplant Medicine and...
TFF Pharmaceuticals to Participate in the 36th Annual Roth Conference – March 17-19, 2024
14 mars 2024 16h47 HE
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, March 14, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals to Present Data from Phase 2 Trial of Voriconazole Inhalation Powder (TFF VORI) for the Treatment of Invasive Pulmonary Aspergillosis at the 11th Advances Against Aspergillosis & Mucormycosis Conference
24 janv. 2024 08h00 HE
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, Jan. 24, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for Presentation at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meeting
09 janv. 2024 08h00 HE
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, Jan. 09, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals Announces Positive Initial Data from Ongoing Phase 2 Trials of TFF VORI and TFF TAC
19 déc. 2023 06h00 HE
|
TFF Pharmaceuticals, Inc.
Treatment with TFF VORI resulted in positive treatment outcomes based on clinical, mycologic and radiologic responses while maintaining a favorable safety/tolerability profile, with no all-cause...
TFF Pharmaceuticals to Host Webcast and Conference to Review Initial Data from the Ongoing Phase 2 Trials of TFF VORI and TFF TAC
18 déc. 2023 16h01 HE
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, Dec. 18, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals Announces Reverse Stock Split
15 déc. 2023 07h00 HE
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, Dec. 15, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals Appoints Thomas B. King to Board of Directors
13 déc. 2023 08h00 HE
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, Dec. 13, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals Appoints Catherine Lee, J.D. to Board of Directors
30 nov. 2023 08h00 HE
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, Nov. 30, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...